Who are Botox's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Onabotulinumtoxin A, Chemodenervation (4 months), Botulinum Toxin-A injection, Botulinum Toxin Type A 900kD, Botulinum Toxin Type A 900kDa, OnabotulinumtoxinA 100 UNT.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/onabotulinumtoxina.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Botox — Competitive Intelligence Brief

Botox (ONABOTULINUMTOXINA) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Acetylcholine Release Inhibitor [EPC]. Area: Neuroscience.

marketed Acetylcholine Release Inhibitor [EPC] SNAP-25 Neuroscience Live · refreshed every 30 min

Target snapshot

Botox (ONABOTULINUMTOXINA) — Allergan. BOTOX blocks neuromuscular transmission by inhibiting acetylcholine release through cleavage of SNAP-25.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Botox TARGET	ONABOTULINUMTOXINA	Allergan	marketed	Acetylcholine Release Inhibitor [EPC]	SNAP-25	2010-01-01
Onabotulinumtoxin A	Onabotulinumtoxin A	Wake Forest University Health Sciences	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Chemodenervation (4 months)	Chemodenervation (4 months)	University of Wisconsin, Madison	marketed	Botulinum toxin	SNARE complex (synaptobrevin, SNAP-25, syntaxin)
Botulinum Toxin-A injection	Botulinum Toxin-A injection	Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust	marketed	Neurotoxin; neuromuscular blocking agent	SNARE complex (specifically cleaves SNAP-25)
Botulinum Toxin Type A 900kD	Botulinum Toxin Type A 900kD	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin Type A 900kDa	Botulinum Toxin Type A 900kDa	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 100 UNT	OnabotulinumtoxinA 100 UNT	University of South Florida	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Acetylcholine Release Inhibitor [EPC] class)

BioActive Nutritional, Inc. · 2 drugs in this class
Cairo University · 1 drug in this class
Elan Pharm · 1 drug in this class
GlaxoSmithKline K.K. · 1 drug in this class
HUGEL INC · 1 drug in this class
Merz Pharms · 1 drug in this class
REVANCE THERAPEUTICS, INC. · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
Allergan · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Botox — Competitive Intelligence Brief. https://druglandscape.com/ci/onabotulinumtoxina. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab